Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD4 | Q53EL6 | 4/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.31 |
| ▸ | FDPS | P14324 | 3/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24023289 | 0.97 | PDCD4 (0.36) | PDCD4NR1I2CA1CA9DUSP3 | |
| SCHEMBL7296440 | 0.85 | PDCD4 (0.41) | PDCD4DUSP3GPR84FFAR1 | |
| SCHEMBL7294647 | 0.78 | GLS2 (0.44) | PDCD4 | |
| SCHEMBL7293103 | 0.74 | PDCD4 (0.40) | PDCD4 | |
| SCHEMBL9631359 | 0.68 | NR1I2 (0.36) | PDCD4NR1I2 | |
| SCHEMBL24376718 | 0.66 | DUSP3 (0.42) | PDCD4DUSP3GPR84FDPSFFAR1 | |
| SCHEMBL6911323 | 0.65 | DNM1 (0.37) | NR1I2GPR84FDPS | |
| SCHEMBL19374387 | 0.64 | GPR84 (0.40) | NR1I2GPR84FDPSFFAR1 | |
| SCHEMBL9631580 | 0.63 | LMNA (0.35) | NR1I2GPR84 | |
| SCHEMBL3462845 | 0.63 | LMNA (0.35) | NR1I2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | NUDT1, RNMT, ADAR | PDCD4 4419/4885NR1I2 4826/4885CA1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.